Figure 1.
Kaplan-Meier curves for overall survival in patients with locoregionally advanced nasopharyngeal carcinoma treated with cisplatin- and fluorouracil-based chemoradiotherapy.
(A) Survival time based on the MPO rs2243828 TT, CT and CC genotypes. (B) Survival time based on the MDM2 rs2279744 TT, GT and GG genotypes. (C) Survival time based on the MPO rs2243828 TT and CT/CC genotypes. (D) Survival time based on the MDM2 rs2279744 TT and GT/GG genotypes.
Figure 2.
Kaplan-Meier curves for progression-free survival in patients with locoregionally advanced nasopharyngeal carcinoma treated with cisplatin- and fluorouracil-based chemoradiotherapy.
(A) Survival time based on the ERCC1 rs3212986 CC, CA and AA genotypes. (B) Survival time based on the ERCC1 rs3212986 CC and CA/AA genotypes. (C) Survival time based on the MDM2 rs2279744 TT, GT and GG genotypes. (D) Survival time based on the MDM2 rs2279744 TT and GT/GG genotypes. (E) Survival time based on the MPO rs2243828 TT, CT and CC genotypes. (F) Survival time based on the MPO rs2243828 TT and CT/CC genotypes. (G) Survival time based on the ABCB1 rs2032582 GG, GT, TT, AG, AT and AA genotypes. (H) Survival time based on the ABCB1 rs2032582 GG/GT/TT/AG and AT/AA genotypes.
Figure 3.
Kaplan-Meier survival curves for the three different risk groups classified by prognostic score models.
(A) Overall survival. (B) Progression-free survival.
Figure 4.
Receiver operating characteristic curves of prognostic score models (PSMs) and overall stage.
(A) PSM and overall stage for overall survival. (B) PSM and overall stage for progression-free survival.